Clinical Study Data
Clinical Studies
It is Declinol’s policy to study and test its products under independent clinical conditions. The studies focus not only on important numerical data, but also on the practical aspects of the addiction and withdrawal as the Client’s experiences it. In other words, numerical improvements aside, does the Client feel better? Do they think they made good progress? If they don’t, then positive-looking clinical test data will not matter to a Client, their support team, family, or friends. Client feedback is collected (whether positive or negative) and Client Testimonials are encouraged during and after the product program so we may further understand the product’s effectiveness- or areas that may be opportunities for improvement. Testing protocols are continuously expanded and improved, and the Practitioners and Client input is invaluable in data gathering and the quest to help those seeking to conquer difficult addictions
Declinol Study
Declinol is a scientifically-formulated to support individuals who would like to control and manage their alcohol consumption. Declinol contains a unique combination of standardized botanicals (chosen for their strong history of use in traditional systems), amino acids and vitamins. Like many negative lifestyle habits, alcohol consumption can be a habit hard to break because of the physiological changes that result from chronic intake of alcohol. Chronic exposure to alcohol affects the equilibrium in neurotransmitters systems that control motivational processes, including reward and stress.
When these neural systems are out of balance, the body seeks to reinforce the reward/pleasure circuits, resulting in strong physical cravings when alcohol consumption is reduced. Reducing the cravings is not as simple as a little will power— even if you can quit, setbacks are a strong possibility. It is often necessary to either provide the brain with the very neurotransmitters that are out of balance or inhibit their breakdown. The Declinol Formula provides ingredients that have been shown to help support craving control through multiple pathways, resulting in stabilized neurotransmitter levels and a healthier neurotransmitter equilibrium. By tapering over safe periods of time, Declinol helps people eliminate the need to ingest alcohol. As amount of alcohol is decreased, body’s neurotransmitter physiology is allowed to rebalance itself naturally.
Daidzin *2-7
For Declinol, a 60 day open label pilot study was conducted on 10 subjects chosen based on their the AUDIT Questionnaire. The AUDIT is a test developed by the World Health Organization (WHO). This test was created to be applicable on a global basis and was in fact validated in a study utilizing patients from 6 different countries. The AUDIT questionnaire has been found to be very efficient and has shown a high sensitivity (83%) and specificity (90%).
The study was overseen by Dr. Zainab Contractor, a Board Certified Neurologist practicing in Ohio. An exit interview was also conducted at the end of study that looked at reduction in cravings; ability to cut back on quantity consumed, response in mood , physical and psychological desire for alcohol, sense of calm, sleep patterns, and overall sense of health.
Following the study, the subjects re-took the AUDIT questionnaire when filling out the exit interview. The average starting score for the AUD was 16.1. The post study score average was 3.7. In addition, 90% of subjects cut back or quit drinking and also reduced or eliminated cravings. Seven out of 10 people had less desire for alcohol either physically or psychologically. Half of the group experienced better sleep, while 9 of 10 respondents felt better overall. Interestingly, all subjects said they would recommend Declinol to anyone attempting to gain control over alcohol.
Journal of Addiction Research and Therapy

References:
1. http://www.niaaa.nih.gov/alcohol-health
2. Identification of isoflavone glycosides in Pueraria lobata cultures by tandem mass spectrometry. Prasain JK, Reppert A, Jones K, Moore DR 2nd, Barnes S, Lila MA.Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. jprasain@uab.edu
3. The isoflavone puerarin reduces alcohol intake in heavy drinkers: A pilot study.Penetar DM, Toto LH, Farmer SL, Lee DY, Ma Z, Liu Y, Lukas SE. Behavioral Psychopharmacology Research Laboratory, McLean Hospital, Belmont, MA 02478, United States; Department of Psychiatry, Harvard Medical School, Boston, MA 02115, United States.
4. The Potential of Herbs and their Derivatives in Treating Addiction
Meletis CD, Zabriskie N. Natural approaches to treating addiction. Altern Complement Ther. December 2008;14(6): 275-281.
5. Alcohol Clin Exp Res. 1996 Apr;20(2):221-7.Suppression of alcohol intake after administration of the Chinese herbal medicine, NPI-028, and its derivatives.Overstreet DH, Lee YW, Rezvani AH, Pei YH, Criswell HE, Janowsky DS. Skipper Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, Chapel Hill 27599-7178, USA
6. Carlson AJ, Torchiani B, Hallock R. Contributions to the physiology of the stomach. XXI: The supposed actions of the bitter tonic on the secretion of gastric juice in man and dog. JAMA, 1915;64(1):15-17.
7. Meyerhof W. Elucidation of mammalian bitter taste. Rev Physiol Biochem Pharmacol, 2005;154:37-72.
8. Behrens M, Meyerhof W. Gustatory and extragustatory functions of mammalian taste receptors. Physiol Behav, 2011;105(1): 4-13.
9. Valussi M. Functional foods with digestion-enhancing properties. Int J Food Sci Nutr, 2011[Epub ahead of print]
10. Finger TE, Kinnamon SC. Taste isn’t just for taste buds anymore. F1000 Biol Rep, 2011;3:20.
11. Wolf S, Mack M. Experimental study of the action of bitters on the stomach of a fistulous human subject. Drug Standards, 1956;24(3):98-101.
12. Mills SM, Bone K. Principles and Practice of Phytotherapy. Modern Herbal Medicine. Churchill Livingstone, Edinburgh, 2000:38-41.
13. Gebhardt R. Stimulation of acid secretion by extracts of Gentiana luteaL. in cultured cells from rat gastric mucosa. Pharm Pharmacol Lett, 1997;7(2-3):106-108.
14. Wegener T. Anwendung eines Trockenextraktes aus Gentiana lutea radix bei dyspeptischem Symptomenkomplex. ZPhytother, 1998;19:163-164.
15. http://www.ncbi.nlm.nih.gov/pmc/art/PMC13/
16. http://www.ncbi.nlm.nih.gov/pmc/art/PMC3/
17. http://www.ncbi.nlm.nih.gov/pubmed/17250611
18. http://www.ncbi.nlm.nih.gov/pubmed/17250611
19. http://www.ncbi.nlm.nih.gov/pmc/art/P743/
20. http://www.lifescience.com/Amino.aspx
21. www.ncbi.nlm.nih.gov/pubmed/dopt=Abstract
22. http://www.drugs.com/npp/bupleurum.html
23. http://apps.who.int/medicinedocs/en/d/Js220
24. http://www.ncbi.nlm.nih.gov/pubmed/16265986?dopt=Abstract
25. http://www.itmonline.org/arts/rehmann.htm
26. http://www.ncbi.nlm.nih.gov/pubmed/23034094
27. Yukmijihwang-tang derivatives enhance cognitive processing in normal young adults: a double-blinded, placebo-controlled trial. Park E, Kang M, Oh JW, Jung M, Park C, Cho C, Kim C, Ji S, Lee Y, Choi H, Kim H, Ko S, Shin M, Park S, Kim HT, Hong M, Bae H. Department of Psychology, Korea University, Seoul, Korea.
28. http://www.ncbi.nlm.nih.gov/articles/P7913/
29. http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC1380207/
30. http://www.ncbi.nlm.nih.gov/pmc/art/P43/
31. Mayer, J, -Functional Foods for Health Program, USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA
32. http://www.ncbi.nlm.nih.gov/pubmed/19757811
33. Keller, B.C., Liposomes in Nutrition, Trends in Food Science & Technology 12 (2001) 25–31
34. Yoko Shojia,b, and Hideki Nakashimaa, Nutraceutics and Delivery Systems, Journal of Drug Targeting, 12(6):385-391, 2004
35. http://www.biopharmasci.com/nano.pdf
36. Torchilin VP. (2006)Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
Keller, B, PhD, Liposomes, Power Point http://www.biopharmasci.com/doc/nanosorb.ppt